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Summary: A radioimmunoassay for the determination of human urinary kallikrein was developed. The sensitivity of
the assay was 0.5 §/1. Dose-response curves of human submandibular and parotid saliva, sweat, pancreatic juice and
bile paralleled the standard curve obtained with purified human urinary kallikrein. Substances with similar antigenic
determinants were also found in human serum, ascites, seminal plasma, amniotic fluid, cervical mucus, tears, liquor
and faeces, but not in human breast milk and gastric juice. Moreover, immunoreactive material was detected in the
urine of guinea pigs, orangoutangs and chimpanzees, but not in the urine of rats, cats and rabbits. Porcine acrosin
and kallikrein, as well as bovine trypsin and chymotrypsin, showed no cross reactivity.
Radioimmunoassay far Kallikrein im Harn des Menschen.
Bestimmung von menschlichem Harnkallikrein, IL
Zusammenfassung: Ein Radio ünmunoassay zur Bestimmung von menschlichem Harnkallikrein wurde entwickelt. Die
untere Nächweisgrenze der Methode betrug 0,5 £/1. Die Dosis-Wirkungskurven für Speichel der Submanibularis- und
Parotisdrüse, von Schweiß, Pankreassaft und Galle lagen parallel zu denen von gereinigtem menschlichen Harnkalli-
krein. Substanzen mit ähnlichen Antigendeterminanten fanden sich auch in menschlichem Serum, Ascites, Seminal-
plasma, Amnionflüssigkeit, Cervixmucus, Tränen, Liquor und Stuhl, jedoch nicht in der Muttermilch und im Magen-
saft. Kreuzreagierendes Material wurde auch im Urin von Meerschweinchen, Orang Utan und Schimpansen, dagegen
nicht im Urin von Ratte, Katze und Kaninchen entdeckt. Auch ergab sich keine Kreuzreaktion mit Akrosin oder
Pänkreaskallikrein vom Schwein sowie Trypsin und Chymotrypsin vom Rind.
introduction
,r , , _ t _ . r . , „.Various methods for the determination of urinary kalli-
krein1) are available, Biological assays such as the blood
pressure response of dogs (1) to intravenous injection of
urine, the vasodilator effect on the perfused hindleg of
a dog and the direct effect of urine on the isolated rat
uterus (2, 3) are not suitable for routine purposes.
Other methods are based on the hydrolysis either of
synthetic substrates1), such as Bz-Arg-OEt (4), Tos^Arg-
m C^7 Tvr (f>\ Ac-Phe-Are-OEt ( 7UMe (5 ), LbZ-1 y -UJNp b), C-rn g Uili ^ /;,
/?-Val-Leu-Arg^NHNip (8) or of the natural substrate
kininogen (9, 10, 1 1). These assays are not specific for
kallflcrein and, because of the presence of inhibitors and
other proteases, do not allow the direct measurement
of kallikrein iii tissues or body fluids other than urine.
This report describes a radioimmunoassay for the deter-
mination of human urinary kallikrein which partly
overcomes these problems. The lower limit of detection
^0.5
 §/1 Immunologically identical material was
found ^ ^  ^ .^  rf ^  submandibular and parotid^^
 pancreatic juicej bile and sweat; partially cross
reactillg material was detected in serum, seminal plasma,
*) Abbreviations:
Bz-Arg-OEt: Na-benzoyl-Z,-arginine ethyl ester
tos-Arg-OMe: Tosyl-Z,-arginine methyl ester
Cbz-Tyr-ONp: Carbobenzoxy-I-tyrosine-p-nitrophenyl ester
Ac-Phe-Aig-OEt: Acetyl-jL-phenylalanyl-Z,-arginine ethyl ester
KI£. xaiuiaein inhibitor units
Enzymes: Kallikrein (EC 3.4.21.8)
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ascites, amniotic fluid, cervical mucus, tears, liquor and
faeces.
Material and Methods
Human urinary kallikrein used for radioiodination and as a
standard was purified as described (12). Complete and in-
complete Freund's adjuvant was purchased from Difco Lab.
Detroit, bovine serum albumin from Roth, Karlsruhe, rabbit
serum from Behringwerke Marburg, Sephadex G-100 from
Pharmacia Uppsala, Sweden, Biogel P-6 and P-60 from Bio-Rad,
M nchen, .D-Val-Leu-Arg-NHNp from Kabi Sweden; Aprotinin
(Trasylol 20000 KIE/ml) and pig pancreatic kallikrein
(1300 KE/mg) were kindly provided by Bayer AG, Wuppertal,
pig acrosin by M ller & Fritz (24). Crystalline bovine trypsin
and chymotrypsin were purchased from Novo Industri.
Sample collection
24-hour urine samples of male and female patients and normal
persons were collected. Urine samples of orangoutangs and
chimpanzees were gifts of the zoological garden of Munich.
Submandibular and parotid saliva, gained by selective catheriza-
tions of the glandular ducts, was collected before and after
oral administration of 2 ml 100 g/1 citric acid. Pancreatic
and duodenal juice was collected by a duodenal catheter in an
X-ray controlled position, or by a pancreatic fistula, which had
arisen postoperatively. Bile fluid was collected externally by
a postoperatively indwelling T drain of the bile duct, amniotic
fluid by amniocentesis in the first trimenon, ascites by trans-
abdominal puncture of patients with decompensated liver
cirrhosis. Samples of serum and seminal plasma were obtained
from healthy volunteers. All samples were centrifuged at lOOOtf
for 20 minutes and immediatelly frozen at - 40 °C.
Buffers
Buffer A 0.4 mol/1 KH2PO4, Na2HPO4, pH 7.5
Buffer B 0.05 mol/1 KH2PO4, Na2HP04,0.15 mol/1 NaCl,
200 mg/1 merthiolate, pH 7.5
Buffer C 0.05 mol/1 KH2PO4, Na2HP04, 0.15 mol/1 NaCl,
2 g/1 bovine serum albumin, 200 mg/1 merthiolate,
pH 7.5
Buffer D 0.01 mol/1 KH2PO4, Na2HP04, 0.15 mol/1 NaCl,
100 g/1 bovine serum albumin, 200 mg/1 merthiolate,
PH7.5
Buffer E 0.01 mol/1 KH2PO4, Na2HP04, 0.1 mol/1 NaCl,
10 g/1 bovine serum albumin, 0.01 mol/1 EDTA,
200 mg/1 merthiolate, pH 7.5
Kallikrein activity
Kallikrein activity was measured using the substrate D-Val-Leu-
Arg-NHNp (8).
Immunization
0.6 mg kallikrein in 1 ml saline was mixed with 2 ml complete
Freund's adjuvant and injected intradermally (two paravertebral
areas) into (2.5-3.5 kg) white New Zealand rabbits.
Intravenous booster injections were given 21 and 28 days after
the initial injection. Antisera were collected by cardiac puncture
10 days later and stored at - 80 °C. A working solution was
prepared by diluting the antiserum with buffer D. The»specificity
of the antiserum was checked by immunodiffusion, immuno-
electrophoresis and inhibition studies as described (13). Precipitat-
ing antirabbit IgG serum was produced in goats. 1 mg rabbit
7-globulin (Serva Heidelberg), 5 mg mycobacterium tuberculosis,
1 ml saline and 1 ml Freund's complete adjuvant were homo-
genized and injected intradermally at 8 sites. Booster injections
were given twice at intervals of 4 weeks using incomplete Freund's
adjuvant. 8 days after each injection serum was tested for anti-
body titer by the double diffusion test of Ouchterlony and
by radioimmunoassay.
Radioiodination
Kallikrein was iodinated by a modification of the chloramine-T
method (14) described by Erhardt et al. (15). 2.5 Mg human
urinary kallikrein in 5 μΐ buffer B, 40 μΐ Na 12SI solution
(14.8 MBq = 0.4 mCi) in buffer A were mixed and the reaction
was started by addition of 10 μΐ (30 Mg in buffer B) chloramine
T. After 20 s the reaction was stopped l?y addition of 20 μΐ
(60 μg) sodium metabisulfite and 200 μΐ buffer C. The reaction
mixture was than transferred toia column with 50 μΐ of a 10 g/1
potassium iodide solution, the column was eluted with buffer B
(40 ml/h). 1.1 ml fractions were collected in disposable poly-
propylene tubes containing 200 μ! b |fer C. Two radioactive
peaks were eluted. the fraction representing the maximum of
the first peak was rechromatographed on a Biogel P-60 column,
1.5 X 60 cm, equilibrated with buffer D, and eluted with buffer
B (40 ml/h). The radioactivity of the fractions was determined
and 3-4 fractions each of the ascending, the middle and the
descending part of the peak corresponding to the elution volume
of were pooled, diluted with buffer E to a final radioactivity of
about 200000 counts/mm X ml and frozen in 10 ml fractions
at-40°C. -
Radipimmunoassay conditions
Human urinary kallikrein standard samples, human urinary
[12S1] kallikrein, unknowns and goat antirabbit IgC were diluted
in b ffer E. 3.3 ml/1 of rabbit serum were added to the human
urinary [125I] kallikrein solution, 0.1 ml b ffer E, 0.1 ml labelled
human urinary kallikrein (approximately 20000 counts/min)
and 0.1 ml antiserum in an appropriate dilution were pipetted
into disposable reaction tubes (1.8 X 5.5 cm). Under routine
conditions the dilution was 1:32000.
The reaction mixture was incubated at 22 °C for 24 hours and,
in order to separate the bound and free kallikrein, 0.1 ml of
the second antibody (antirabbit γ-glpbulin, produced in goats)
was added in a dilution of 1:30, mixed and left at 4 °C for
another 4-8 hours. After centrifugation at 2000 g for 30 min,
the supernatant was decanted, the tube was wiped with filter
paper and the radioactivity of the precipitate measured. All
calibration samples were set up in triplicate (tab. 1). Standard
curves were constructed by plotting the fraction of bound
radioactivity, B-N/B0-N (B: counts bound, B0: counts read for
zero d se, N: ηόη specifically bound counts) against the dose
of human uriuary kallikrein either in a Ipgit-lpg mode or in a
linear-log mode. The assays were evaluated by a computer
program employing the spline approximation method (16). To
test the accuracy of the radioimmunoassay samples of human
urine, pancreatic juice and saliva of the parotid gland were
Tab. 1. Scheme of human urinary kallikrein radioimmunoassay.
Sample Zero n- Total
binding specific activ-
binding ity
Buffer Ε
Standard or sample
Anti-human urinary
(ml)
B
0.1
0.1
0.1
(ml)
Bo
0.2
-
0.1
(ml)
Ν
0.2
-
-
(ml)
Τ
—
-
-
kallikrein antibody
(rabbit) dil. 1:32000
Human urinary [12SI] 0.1 0.1 0.1 0.1
kallikrein (0.1 ng) +
rabbit serum dil. 1:300
24 h at 22 °C
Anti-rabbit rglobulin 0.1 0.1 .0.1
antibody (goat) dil. 1:30
8 h a t 4 ° C -
Centrifugation: 2000 £, 30 min
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measured in three different concentrations (urine: 2.9; 2.6; 3.3;
pancreatic juice: 16; 9.5; 11.5; parotid saliva: 46; 53; 52 Mg/1)
in six different assays. The same solutions were used as "internal
standard" in all assays performed.
Specificity
Bovine trypsin and chymotrypsin (0.01 -1.0 g/1), porcine acrosin
and pancreatic kallikrein (1-100 mg/1) and urine samples from
orangoutang and chimpanzee were studied for cross reactivity.
Results
lodination and binding of
human urinary [12SI] kallikrein to antisera
After labelling by the chloramin -T method the reaction
mixture was immediately transferred to a Biogel P-6
column, which effectively separated the labelled kalli-
krein from free iodine. The fraction with the highest
specific activity was rechromatographed on Biogel P-60.
In one experiment all fractions were tested for binding
with excess antibody. The results are shown in figure 1.
The maximum binding was found for fraction 29. There-
fore, fractions no. 28 to 31 were pooled and diluted to
the final concentration (20000 counts/min) for the use
in radioimmunoassay. Reproducible results were obtained
for up to 6 weeks. The specific activity of this human
urinary [125I] kallikrein preparation was 1.48 MBq/Mg
(40 μα/μ&). 1 ml of the solution contained approxi-
mately 1 ng of human urinary [125I] kallikrein. The
maximum binding of the pooled fractions was 57%.
Sufficiently high antibody titers were found in all 7
rabbits. The titers expressed as 50% binding of 0.1 ng
labelled human urinary kallikrein were 1:4 Χ 104 to
1:2 X 10s (fig. 2). With dilutions of the different anti-
sera, yielding a B/T ratio of 30-38%, identical slopes
and positions of the standard curves were obtained.
22 23 24 25 26 27 fffl 29 30 31 32 33
Fraction number
Fig. 1. Rechromatqgraphy of desalted human urinary j
kallikrein on a Biogel P-60 column (1.5 X 60). Fraction
volume: L6 ml, elutipn buffer: B, flow rate 40 ml/h.
.—. specific binding of human urinary I12*I] kallikrein
for antibody at human urinary kallikrein antiserum dilu-
tion 1:1000, conditions see methods; o^-o radioactivity/
tube X 30 s.
0.6
0.5
(U
0.3
is
I °·2
0.1
1:1000 1:4000 1:16000 1:32000
Antiserum dilution
1:128000 1:512000
Fig. 2. Titration curves of 4 rabbit anti-human urinary kallikrein
sera. The tubes, containing 0.2 ml buffer E, 0.1 ml anti-
human urinary kallikrein serum dilution and 0.1 ml human
urinary [125IJ kallikrein (20000 counts/min) were
incubated at 22 °C for 24 h. Bound human urinary [125IJ
kallikrein was precipitated by adding 0.1 ml of the dilu-
tion (1:30) of goat antirabbit-7-globulin serum. The anti-
serum dilutions given indicate the final dilution. Rabbit
no. *—A 4, α—ο 5, ·—« 6, Δ—Δ 7.
Time and temperature dependence
of the antigen antibody reactions
In order to find the optimal incubation conditions for
the radioimmunoassay the time dependence of the
binding of human urinary [125I] kallikrein to the anti-
body was studied at 4, 22 and 37 °C. The results are
summarized in figure 3. The highest binding rate was
observed at 22,°C, equilibrium was reached after 48
hours. The increment of binding between 24 and 48 h
was only 0.09 of maximum binding. Therefore, 24 h
incubation was used for routine purposes. The kinetics
of the reaction with goat antirabbit IgG serum was
studied at 4 and 22 °C. The equilibrium of precipitation
of radioactivity was reached after 8 h, optimal binding*
was obtained at 4 °C.
Standard curves and sensitivity
The sensitivity of the radioimmunoassay can be increased
by preincubating unlabelled antigen with the antibody
before the labelled antigen is added. By means of
48 hours "cold preincubation" the lower limit of detec-
tion was reduced from 0.9 to 0.4 Mg/1, the 50% intercept
from 10.2 to 2.5 and the slope from - 1.1 to - 1.3 under
routine assay conditions (fig. 4).
Precision
The intraassay coefficient of variation (N = 6) was 4-7%
for urine (range 2.9 to 46 μg/l), for saliva of the parotid
gland 3-8% (range 3.3 to 52 Mg/l) and for pancreatic
juice 4-8% (range 2.6 to
JL Clin. Chem. Clin. Biochem. / Vol. 18, 1980 / No. 7
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0.2 -
0.1
37 °G
3 6 12 48
Incubation time [h]
72
4°C
22 °C
Incubation time [h]
24 48
Fig. 3. Time and temperature dependence of the binding of
human urinary [12SI] kallikrein to the anti-human urinary
kallikrein antibody (a) and antny-globulin antibody (b)
resp.
The interassay coefficient of variation of identical samples
(N = 6) containing 2,9,16,46 Mg/1, each measured at
6 different occasions, was 4—13%.
Specificity
Cross reaction of other serine proteinases with anti-
human urinary kallikrein serum was tested under radio-
immunoassay conditions. No cross reaction was
observed for bovine trypsin and chymotrypsin, pig
pancreatic kallikrein and pig acrosin, rat urine, homo-
genate of rat tubules (17), rabbit and cat urine. In
contrast, cross reacting material was found in the urine
of guinea pigs, orangoutangs and chimpanzees. In human
samples immunologically active material was found in
the saliva of submandibular and parotid gland, pancrea-
tic juice, bile, sweat, serum, ascites, seminal plasma,
amniotic fluid, cervical mucus, tears, liquor and faeces,
but not in gastric juice and breast milk.
A necessary though not sufficient criterion of irhmuno-
logical identity is parallelity of dose response curves of
the sample and the standard substance measured radio^
immunologically. This criterion was fulfilled for human
urine, saliva of the submandibular and parotid gland,
pancreatic juice, bile and sweat (fig. 5,6). The kallikrein
content in urine was 0—300 μg/l, in pancreatic juice
300-12000 μ%/1 and in saliva of the submandibular
and parotid gland 400-2000 μβ/1.
Dose-response curves of serum, ascites, seminal plasma,
amniotic fluid, cervical mucus, tears, liquor arid human
1.0
I °·6
1 0.4
ο00
 0.2
0 0.12 0.25 Q5 1 2 4 8 16 32 64 128
Kallikrein [jig/I]
Fig. 4. Influence of preincubation time of unlabelled human
urinary kallikrein on standard curves. Conditions see
. Table 1.
•—· Incubation of standard, anti-human urinary
kallikrein serum and tracer for 24 h.
Δ
—
Δ
 Preincubation of standard and anti-human urinary
kallikrein serum for 24 h, followed by 24 h incuba-
tion after addition of tracer.
•—· Preincubation of standard and anti-human urinary
kallikrein serum for 48 h, followed by 24 h incuba-
tion after addition of tracer.
lower limit of detection.
0.9
0.8
-Pf 0.7
-l»? o*
* 0.5
S ΟΛ
Ι °·31 °·2
l 0.1
Ί/4096 1/512
E D
1/4096 1/64
1/2048Ι ι 1/64ι
1/64
Dilution
I I
8 16 32 64 128
Kaltikrein [μς /(]
Fig. 5. Dose response curves of purified human urinary kallikrein
and human body fluids in the human urinary kallikrein
, radioimmunoassay. The reactivity is identical. Results
are expressed in the logit-log transformation, normalized
to maximum counts bound (B0).
•r-r-· Standard human urinary kallikrein, m^-m human
urine, α—α parotid saliva, Δ—Δ submandibular saliva,
ο—ο pancreatic juice.
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? P 0.9
»U
>:
I 0-8
l 0.7
l 0.6
•o
l 0.5
-
 ΟΛ
f 0.3
0.2
0.1
1:32 1:16 1:8
·+
1:4
-h
1:2 1:1 Bile.Sweoi
1:80 1:40 1:20 1:10 Urine
0.25 0.5 1.0 2 4
Kallikrein l/ig/l)
Fig. 6. Dose response curves of human urinary kallikrein and
human body fluids in the human urinary kallikrein radio-
immunoassay. Standard and samples were preincubated
for 48 h, before labelled human urinary kallikrein was
added, followed by a incubation time of 24 h. The
reactivity of human urinary kallikrein and body fluids is
identical.
•—· standard human urinary kallikrein, α—α bile,
ο—ο sweat, Δ—Δ urine.
f0.9
r
^ ο,θ!>
0.7
l 0.6
l 0.5
J 0.4
f 0.3
0.2}
0.1
1:32 1:16 1:8 V.4 1:2 1:1
JL025 as to ?
KqUikfeml/ig/l)
16
Fig. 7. Dose response lines for ·—· standard human urinary
kallikiein, ·—· amniotic fluid, A—A seminal plasma,
O-TS-D s cites, Δ—Δ serum, Ρ—ο chimpanzee urine.
faeces, urine samples of guinea pigs, orangoutangs and
chimpanzees were neither parallel to the human urinary
kallikrein standard curves nor to each other (fig. 7).
Recovery test
Several recovery tests have shown the good precision of
the method. Different quantities of purified human
urinary kallikrein were added to antigen-free rat urine,
in order to measure the added and recovered kallikrein
ratio, (tab. 2).
Stability
The storage of pancreatic juice, saliva and urine at 4 °C
and 22 °C from 4 to 68 hours, as well as freezing and
thawing four times, had no influence on the kallikrein
content measured by the radioimmunoassay (tab. 3).
Discussion
The radioimmunoassay technique, which is sensitive
and specific, should be very suitable for studies on the
physiological and pathophysiological role of glandular
kallikreins. In the same species, the different glandular
kallikreins can be measured by a radioimmunoassay for
Tab. 2. Recovery test.
Human
urinary
kallikrein
added
Human urinary
kallikrein recovered
(Mg/D
N Recovery
50
5
52.9 ± 2.6
6.6 ± 1.03
8
8
105.8 ±4.9
130 ± 1.5
Concentrations of purified human urinary kallikrein indicated
above were added to 1 ml of antigen free rat urine and measured
by radioimmunoassay.
Tab. 3. Stability of human glandular kallikrein during storage
determined by radioimmunoassay.
Results are given as per cent binding (- — · 100).BO — Ν
Ul
2
3
P 1
2
3
4
S 1
2
3
4
Oh
87.5
94.8
61.7
12.6
7.7
5.7
8.8
50.8
15.4
39.9
16.7
4h
22 °C
79.6
86.8
56.2
9.3
7.8
5.9
8.9
48.4
15.0
39.5
16.0
68 h
85.6
90.6
61.3
10.9
8.1
7.1
10.3
52.1
16.2
41.7
18;0
4h
4°C
78.8
86.4
53.1
9.6
7.1
5.9
9.1
47.6
15.2
37.8
14.7
68 h
83.3
93.0
59.8
11.6
10.2
6.9
10.4
53.0
17.6
42.5
18.3
Freezing
and
thawing
4 times
84.9
92.0
59.7
12.3
8.5
5.9
8.7
51.5
16.8
45.6
17.8
= urine, Ρ = pancreatic juice, S = saliva
Samples were stored at different temperatures and for different
time intervals.
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any one of them, owing to the high immunological
similarity or even identity of the glandular kallikreins
in one species (18,19,.20, 21). In order to measure
human glandular kallikreins we developed a radioimmuno-
assay for urinary kallikrein.
By use of the chloramine T method, human urinary
kallikrein was iodinated to a specific activity sufficiently
high for use in this assay. The maximal binding of the
tracer to the antibody was 0.62 and no essential loss
of binding was observed for up to six weeks. Best incuba-
tion conditions for the measurement of human urinary
kallikrein in respect to time and temperature were
found to be similar to those described for the radio-
immunoassay of pig pancreatic kallikrein (18). The
sensitivity of the assay was 0.9 g/l and could be
increased about twofold by the technique of "cold
preincubation".
The high specificity of the radioimmunoassay was
demonstrated by employing various proteinases and
biological samples. Some cross reactivity was found
when urine of chimpanzees (fig. 7), orangoutangs and
guinea pigs was measured. However, the dose response
curves did not parallel the human urinary kallikrein
standard curves. These observations can be explained
by partial immunological identity of the glandular kalli-
kreins of these species. No crossreactivity at all was de-
tected for the serine proteases, bovine trypsin and chymo-
trypsin and porcine acrosin. Final proof of non-cross
reactivity of the various human serine proteases is not
yet available; however, in analogy to the results ob-
tained by radioimmunoassay of pig pancreatic (18)
and rat submandibular kallikrein (20), it may be
expected that human proteinases other than tissue
kallikreins do not interfere in the radioimmunoassay
of human urinary kallikrein. Therefore, in contrast
to the assays based on the enzymatic activity of kalli-
krein, the radioimmunological measurement of kalli-
krein is possible in the presence of other proteases. A
further advantage of the radioimmunoassay method
is that storage of biological samples at 4 and 22 °C up
to 68 h, as well as freezing and thawing (tab. 3), have
no influence on the measured kallikrein concentration,
whereas a rapid decrease of the enzymatic activity is
known to occur in frozen samples (11).
The radioimmunoassay was used to measure kallikrein
concentrations in biological samples. The dose response
curves obtained for serum, ascites, seminal plasma,
amniotic fluid, cervical mucus, tears, liquor and faeces
did not parallel the standard curve. Therefore, a direct
quantitative determination of glandular kallikrein in
these samples is not possible. Similar results were
obtained when radioimmunoassays for pig pancreatic
kallikrein (22) and rat urinary kallikrein (23) were
applied to the measurement of glandular kallikrein in
serum and plasma. Dose response curves paralleling the
human urinary kallikrein standard curve were found
for human urine, saliva, bile, pancreatic juice and sweat,
thus allowing the measurement of the kallikrein con-
centration in these samples.
Several explanations for non-parallelity are possible, for
example:
a) inhibitors present in the samples occupy antigenic
sites of [125I] kallikrein thus reducing the binding to
the antibody and interfering in the radioimmunoassay;
b) prekallikrein or modified kallikrein with immuno-
logically different properties interfere;
c) other cross reacting antigens, not yet characterized,
are present in the samples;
d) non-specific interferences.
All these possible interferences and methods for their
elimination have to be investigated further. Final proof
of the presence of glandular kallikrein in the various
biological samples has to come from additional evidence,
not obtained by immunological methods.
The physiological and pathophysiological role of glandu-
lar kallikreins is still unknown to a large degree. The
availability of a radioimmunoassay for human glandular
kallikrein will provide the means to study possible
relationships between pathologic states and the con-
centrations of glandular kallikreins in body fluids and
tissues. Such studies should lead to a better understanding
of the physiological function of the kallikreins.
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